Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Rhea-AI Summary
Perspective Therapeutics (NYSE AMERICAN: CATX) will report full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The company said the results and update will be posted on its newsroom press releases page.
Investors can expect a webcast or press release posting following the market close on that date.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CATX gained 3.19%, reflecting a moderate positive market reaction. This price movement added approximately $16M to the company's valuation, bringing the market cap to $530M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CATX fell 6.37% while momentum peers NNOX, STIM, and OM all screened to the upside, indicating stock-specific action rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Q3 2025 results | Positive | +1.4% | Reported 3Q 2025 results with clinical progress and highlighted cash position. |
| Oct 24 | Q3 results date | Neutral | +3.8% | Announced date and timing for 3Q 2025 results and business update. |
| Aug 13 | Q2 2025 results | Positive | -4.3% | Reported Q2 2025 results with strong cash and R&D-driven wider net loss. |
| Jul 15 | Q2 results date | Neutral | -2.5% | Scheduled Q2 2025 financial results announcement and business update. |
| May 12 | Q1 2025 results | Positive | +1.6% | Reported Q1 2025 results with strong cash and multi-program clinical progress. |
Earnings-related and scheduling releases have generally seen modest, often positive, price moves, with one notable negative reaction to detailed Q2 results.
Over the past year, Perspective Therapeutics has used earnings and quarterly updates to pair financial disclosures with pipeline progress. Q1–Q3 2025 releases highlighted cash balances of up to $212M and funding runways into late 2026, alongside advancement of [212Pb]VMT-α-NET, VMT01, and PSV359. Two prior releases simply scheduled future results dates, similar to today’s full-year 2025 reporting notice. Price reactions around these events were mostly modest and often positive, suggesting the market treated them as incremental rather than transformational catalysts.
Historical Comparison
Past earnings and scheduling releases for CATX have produced modest, mixed moves averaging about 0%, so reactions to this full-year 2025 timing update would fit that historical pattern.
Earnings communications progressed from 1Q to 3Q 2025 results plus two prior scheduling notices, leading into this announcement of the upcoming full-year 2025 report and business update.
Market Pulse Summary
This announcement sets the date for Perspective Therapeutics’ full year 2025 financial results and business update, which are scheduled for March 16, 2025 after the close. Historically, the company has paired earnings with updates on its radiopharmaceutical pipeline and cash runway. Prior quarters highlighted both substantial investment in R&D and solid cash resources. Investors following this name may focus on how full-year numbers compare with earlier unaudited estimates and whether guidance on funding duration or development timelines changes.
AI-generated analysis. Not financial advice.
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) release its full year 2025 financial results?
Where can investors find the CATX March 16, 2025 press release and business update?
Will Perspective Therapeutics (CATX) provide a webcast with the March 16, 2025 results?
What should CATX shareholders expect from the March 16, 2025 business update?
How can investors prepare for Perspective Therapeutics' (CATX) March 16, 2025 announcement?
